We apply our proprietary PhytoProfile™ technology to ensure that every batch of Labeesity® contains at least seven bio-active compounds, including gallic acid. This technology also ensures that we meet the minimum standards stipulated by the SIRIM guide for gallic acid content, which is the most significant compound in SKF7™ that aids weight loss. According to the standard, gallic acid content must exceed 0.2%.

SKF7™ was approved by the United States Food and Drug Administration (US FDA) as a New Dietary Ingredient (NDIN) in 2020 and is expected to receive the European Food Safety Authority (EFSA) clearance as a Novel Food in 2021.

The safety of SKF7™ has also been proven in four toxicity studies, which were conducted by Vimta Labs in India, whose facilities have been audited by the United States FDA and WHO [1].

SKF7™ is currently undergoing the first phase two clinical trial of its kind in Malaysia, Indonesia and India.

Labeesity® has also been approved by governing bodies across Asia including the Singapore’s Health Sciences Authority (HSA), Malaysian National Pharmaceutical Regulatory Agency (NPRA), and the Indonesian National Agency of Drug and Food Control (BPOM) in 2016, 2017, and 2020, respectively.

[1] Vimta Labs Ltd. In Vitro Mammalian Chromosome Abberation Test of Labisia Pumila Aqueous Ethanolic Standardized Extract (SKF7TM) In Cultured Human Peripheral Blood Lymphocytes (0ECD 473). 2018.
[2] Vimta Labs Ltd. Bacterial Reverse Mutation Test of Labisia Pumila Aqueous Ethanolic Standardized Extract (SKF7TM) Using Salmonella Typhimurium Tester Strains (0ECD 471). 2018.
[3] Vimta Labs Ltd. Mammalian Erythrocyte Micronucleus Test of Labisia Pumila Aqueous Ethanolic Standardized Extract (SKF7TM) in Mice Following Oral Gavage Administration (0ECD 474). No date yet.
[4] Vimta Labs Ltd. Repeated Dose (90 days) Oral Toxicity Study of Labisia Pumila Aqueous Ethanolic Standardized Extract (SKF7TM) in Wistar Rats (0ECD 408). 2018.